Abstract
It has been widely accepted that 5HT neurones promote anxiety, in humans as well as in animal models. This could be termed the “classic” hypothesis and it has led to a determined search for drugs which reduce 5HT function, especially agents which have selective actions at 5HT receptor subtypes. However, these novel agents tend to have weak and/or variable effects in animal models and more detailed examination of their actions suggests that not all findings are accounted for by the classic hypothesis. There appear to be circumstances in which increased 5HT activity can reduce anxious behaviour. There is increasing evidence for multiple anxiety mechanisms, which may be able to explain differential patterns of drug effects within and between models. Animal models of anxiety may also detect non-anxiety factors: effects on cognition or on impulsivity could be reflected in some models. This could be important in the light of recent evidence that 5HT-selective reuptake inhibitors are effective in impulsivity disorders. The classic hypothesis of 5HT function in anxiety may be only one part of an increasingly complex story. Unravelling the rest of this story is likely to lead to new insights in our understanding of anxiety and related disorders.
Similar content being viewed by others
References
Almeida SS, De Oliviera LM, Graeff FG (1990) Decreased reactivity to anxiolytics caused by early protein malnutrition in rats. Pharmacol Biochem Behav 36:997–1000
Audi EA, de Olveira RMW, Graeff FG (1991) Microinjection of propranolol into the dorsal periaqueductal gray causes an anxiolytic effect in the elevated plus maze antagonised by ritanserin. Psychopharmacology 105:553–557
Beckett SRG, Lawrence AJ, Marsden CA, Marshall PW (1992) Attenuation of a chemically induced defence response by 5HT1 receptor agonists administered into the periaqueductal grey Psychopharmacology 118:110–115
Blier P, de Monitgny C (1990) Electrophysiological investigation of the adaptive response of the 5-HT system to the administration of 5-HT1A receptor agoinists. J Cardiovasc Pharmacol 15:S42–48
Bockeart J, Dumuis A, Bouhelal R, Sebbe M, Cory RN (1987) Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hippocampal neurons. Naunyn-Schmiedeberg's Arch Pharmacol 335:588–592
Bradley PB, Smounya L, Fenuik W. Fozard JJ, Humphrey PPA, Middlemiss DN, Mylechrane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacol 25:563–576
Cadogan AK, Wright IK, Coombs I, Marsden CA, Kendall DA, Tulloch I (1992) Repeated paroxetine administration in the rat produces an anxiolytic profile in the elevated X-maze and a decreased3H-ketanserin binding. Neurosci Lett Suppl 42:S8
Ceulemans DLS, Hoppenbrowers MLKA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin receptor antagonist, in anxiety disorders: a double blind placebo-controlled study versus lorazepam. Pharmacol Biochem Behav 18:303–305
Charney DS, Heninger GR, Renhard JF, Sternberg DE, Hafstead KM (1982) Effect of intravenousl-tryptophan on prolactin and growth hormone and mood in healthy subjects. Psychopharmacology 77:217–222
Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin functions in anxiety II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92:14–24
Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify serotonergic function. TIPS 8:383–388
Costall B, Kelly ME, Tomkins DM, Tyers MB (1989a) Profile of aciton of diazepam and 5-HT3 receptor antagonists in the elevated X-maze. J Psychopharmacol 3:10P
Costall B, Kelly ME, Naylor RJ, Onaivi ES, Tyers MB (1989b) Neuroanatomical sites of action of 5-HT3 receptor agonists and antagonists for alteration of aversive behaviour in the mouse. Br J Pharmacol 96:325–332
Critchley MAE, Handley SL (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors. Psychopharmacology 93:502–506
Critchley MAE, Njung'e K, Handley SL (1987) 5-HT ligand effects in the social interaction test of anxiety. Br J Pharmacol 92:659P
Critchley MAE, Njung'e K, Handley SL (1992) Actions and some interactions of some 5-HT1A ligand in the elevated X-maze and effects of dorsal raphe lesions. Psychopharmacology 106:484–490
Deakin JFW (1983) Roles of serotonergic systems in escape, avoidance and other behaviours. In: Cooper SJ (ed) Theory in psychopharmacology, vol. 2. Academic Press, New York, pp 149–193
Deakin JFW, Graeff FG (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5:305–315
de Montigny C, Blier P (1992) Effects of antidepressant treatments on 5-HT neurotransmission. In: Marsden CA, Heal DJ (eds) Central serotonin receptors and psychotropic drugs. Blackwell, London, pp 223–238
Den Boer JA, Westenberg HGM (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102:85–94
Dourish CT, Hutson PH, Curzon G (1986) Putative anxiolytics 8-OHDPAT buspirone and TVXQ 7821 are agonists at 5-HT1A autoreceptors in the raphe nuclei. TIPS 7:212–214
Eison AS, Eison MS, Stanley M, Riblet LA (1986) Serotonergic mechanisms in the behavioural effects of buspirone and gepirone. Pharmacol Biochem Behav 24:701–707
Engel JA, Hjorth S, Svensson K, Carlsson A, Liljequist B (1984) Anticonflict effects of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Eur J Pharmacol 105:365–368
Engelman K, Lovenberg W, Sjoerdsma A (1967) Inhibition of serotonin synthesis byp-chlorophenylalanine in carcinoid syndrome. New Eng J Med 227:1103–1108
File SE, Hyde JRG (1979) Can social interaction be used to measure anxiety? Br J Pharmacol 62:19–24
File SE, Johnston AJ (1989) Lack of effects of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. Psychopharmacology 99:248–251
Gardner CR (1985) Recent developments in 5-HT-related pharmacology of animal models of anxiety. Pharmacol Biochem Behav 24:1479–1485
Gardner CR, Guy AP (1985) Pharmacological characterization of a modified social interactin model of anxiety in the rat. Neuropsychobiology 13:194–200
Glaser T, Traber J (1983) Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 88:137–138
Graeff FG (1988) Animal models of aversion. In: Simon P, Soubrié P, Widlocher D (eds) Animal models of psychiatric disorders. Karger, Basel, pp 115–141
Graeff FG (1992) Amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res (in press)
Graeff FG, Schoenfeld RI (1970) Tryptaminergic mechanisms in punished and nonpunished behaviour. J Pharmacol Exp Ther 173:277–283
Graeff FG, Zuardi AW, Gjimiglio JS, Filho EC, Karniol IG (1985) Effect of metergoline on human anxiety. Psychopharmacology 86:334–338
Grantham P (1987) Benzodiazepine abuse. Br J Hosp Med 37:292–300
Gray JA (1982) The neuropsychology of anxiety. Oxford University Press, Oxford
Green S (1991) Benzodiazepines putative anxiolyitics and animal models of anxiety. TINS 14:101–104
Guimaraes FS (1992) 5-HT receptors and consolidation of stressful memories. Behav Brian Res (in press)
Guimaraes FS, Wang M, Deakin JFW (1990a) Ritanserin reduces the expression of a conditioned fear response in neurotic patients. J Psychopharmacol 4:259P
Guimaraes FS, Cosme RA, Zuardi AW, Graeff FG (1990b) Ipsapirone reduces increases in anxiety during a simulated public speaking test. J Psychopharmacol 4:296P
Handley SL (1991) Serotonin in animal models of anxiety: the importance of stimulus and response. In: Cowen P, Idzikowski C (eds) Serotonin, sleep and mental disorder. Wrightson, Petersfield, pp 89–115
Handley SL, McBlane JW (1991) 5-HT — the disengaging transmitter? J Psychopharmacol 5:322–326
Handley SL, McBlane JW (1993) An assessment of the elevated X-maze for studying anxiety and anxiety modulating drugs. J Pharmacol Methods (in press)
Handley SL, Mithani S (1984) Effects of α2-adrenoceptor agonists and antagonists in a maze exploration model of fear-motivated behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 327:1–5
Handley SL, McBlane JW, Critchley MAE, Njung'e K (1992) Multiple serotonin mechanisms in animal models of anxiety: the importance of stimulus and response. Behav Brain Res (in press)
Hensman R, Guimaraes FS, Wang M, Deakin JFW (1991) The effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology 104:220–224
Higgins GA, Bradbury AJ, Jones BJ, Oakley NR (1988) Behavioural and biochemical consequences following activation of 5-HT1-like and GABA receptors in the dorsal raphe nucleus of the rat. Neuropharmacology 27:993–1001
Higgins GA, Jones BJ, Oakley NR, Tyers MB (1991) Evidence that the amygdala is involved in the disinhibitory effects of 5HT3-receptors antagonists. Psychopharmacology 104:545–551
Hodges H, Green S, Glenn B (1987) Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination. Psychopharmacology 92:491–504
Hoyer D, Schoeffter P (1991) 5-HT receptors: subtypes and second messengers. J Rec Res 11:197–214
Iversen SD (1984) 5-HT and anxiety. Neuropharmacology 23:1553–1560
Jenck F, Broekkamp CLR, van Delft AML (1989) Opposite control mediated by central 5-HT1A and non-5-HT1A(5-HT1B or 5-HT1C) receptors on periaqueductal gray aversion. Eur J Pharmacol 161:219–221
Jenck F, Broekkamp CLE, van Delft AML (1990) 5-HT1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats. Psychopharmacology 100:373–376
Kennett GA, Dourish CT, Curzon G (1987) Anti-depressant-like actions of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol 134:265–274
Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects ofmCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164:445–454
Kiser RS, Lebowitz RM (1975) Monoaminergic mechanisms in aversive brain stimulation. Physiol Behav 15:47–53
Klint T (1991) Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated X-maze test in rats. Behav Pharmacol 2:481–489
Kostowski W, Platznik A, Stefanski R (1989) Intra-hippocampal buspirone in animal models of anxiety. Eur J Pharmacol 168:393–396
Kostowski W, Dyr W, Krzscik P (1990) The effects of 5-HT1A receptor agonists in animal models of anxiety and depression. Psychopharmacology 101:S31
Kshama D, Hrishikeshaven HJ, Shanbogue R, Munonyedi US (1990) Modulation of baseline behaviour in rats by putative serotonergic agents in three ethoexperimental paradigms. Behav Neural Biol 54:234–253
Lader MH (1991) Ondansetron in the treatment of anxiety. Presented at the 5th World Congress of Biological Psychiatry, Satellite symposium, The role of ondansetron, a novel 5-HT3 antagonist in the treatment of psychiatric disorders, Florence, pp 17–19
LeDoux JE (1993) Emotional memory systems in the brain. Behav Brain Res (in press)
Lightowler S, Williams IJR, Hegarty J, Kennett GA, Fears RB, Tulloch IF (1992) Anxiolytic effect of paroxetine in the rat social interaction model of anxiety. Br J Pharmacol 106:44P
Lister RG (1990) Ethologically-based animal models of anxiety disorders. Pharmacol Ther 46:321–340
Lopez-Ibor JJ (1988) The involvement of serotonin in psychiatric disorders and behaviour. Br J Psychiat 153 [Suppl 3]:26–39
Luscombe GP, Mazurkiewicz SE, Heal DJ (1992) The 5-HT1A ligand BP 554 mimics the anxiolytic activity of buspirone gepirone and ipsapirone in the elevated plus-maze in rats. Br J Pharmacol 106:220–130P
Mansbach RS, Geyer MA (1988) Blockade of potentiated startle responding in rats by 5-hydroxytryptamine1A receptor ligands. Eur J Pharmacol 156:375–383
Meller E, Goldstein M, Bohmaker K (1990) Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. Mol Pharamcol 37:231–237
Moser PC (1989) An evaluation of the elevated plus-maze test using a novel anxiolytic buspirone. Psychopharmacology 99:48–53
Moser PC, Tricklebank MD, Middlemiss DN, Mir AK, Hibert MF, Fozard JR (1990) Characterisation of MDL 7300EF as a 5-HT1A selective ligand and its effects in animal models of anxiety; comparison with buspirone 8-OH-DPAT and diazepam. Br J Pharmacol 99:343–349
Motta V, Maisonnette S, Morato S, Castrechini P, Brandao ML (1992) Effects of blockade of 5-HT2 receptors and activation of 5-HT1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology 107:135–139
Moulton B, Morinan A (1990) The effect of RS-30199 on anxiety and hippocampal monoamine oxidase activity in the rat. Br J Pharmacol 101:516P
Moyer JA, Lucki I (1985) The piperazine serotonin (5-HT) agonistsm-chlorophenylpiperazine (mCPP) and 6-chloro-2(1-piperzinyl)pyrazine (MK 212) impair avoidance responding in a discrete trial conditioned avoidance procedure. Soc Neurosci Abstr 11:1187
Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ (1986) Review of the side effect profile of buspirone. Am J Med 89[Suppl 3]:17–21
Njung'e K (1990) Effects of some 5-hydroxytryptamine and related ligands in anxiety models. PhD thesis, Aston University, UK
Nutt DJ, Glue P (1989) Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. Pharmacol Ther 44:309–334
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167
Pellow S, Johnston A, File SE (1987) Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes and interactions with yohimbine and FG7142 using the elevated plus-maze test in the rat. J Pharm Pharmacol 39:917–928
Peroutka SJ (1985) Selective interaction of novel anxiolytics with-5-hydroxytryptamine 1A receptors. Biol Psychiatry 20:971–979
Redfern WS, Williams A (1989) Acute effects of centrally acting drugs on the behaviour of rats in an elevated X-maze and a partially shaded holeboard. Br J Pharmacol 97:9P
Robichaud RC, Sledge KL (1969) The effects ofp-chlorophenylalanine on experimentally induced conflict in the rat. Life Sci 8:965–969
Schweitzer E, Rickels K (1991) Serotonergic anxiolytics: a review of their clinical efficacy. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists and 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Wiley, NY, pp 366–376
Sheehan DV, Raj AB, Sheehan K, Soto S (1988) The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 29:815–817
Söderpalm B, Hjorth S, Engel JA (1989) Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacol Biochem Behav 32:259–265
Soubrié P (1988) Serotonin and behaviour, with special regard to animal models of anxiety, depression and waiting ability. In: Osborne NN, Hamon M (eds) Neuronal serotonin. Wiley, NY, pp 255–270
Stein L, Wise CD, Berger BD (1973) Antianxiety actions of benzodiazepines: decrease in activity of serotonin neurones in the punishment system. In: Garattini S, Mussini E, Randall IO (eds) The benzodiazepines. Raven Press, NY, pp 299–326
Tenen SS (1967) The effects ofp-chlorophenylalanine, a serotonin depletor on avoidance aquisition, pain sensitivity and related behaviour in the rat. Psychopharmacology 10:204–219
Thiebot M-H (1986) Are serotonergic neurones involved in the control of anxiety and in the anxiolytic activity of benzodiazepines. Pharmacol Biochem Behav 24:1471–1477
Thiébot M-H, Hamon M, Soubrié P (1983) The involvement of nigral serotonin innervation in the control of punishment-indiced behavioural inhibition in rats. Pharmacol Biochem Behav 19:225–229
Thiébot M-H, Le Bihan C, Soubrié P, Simon P (1985) Benzodiazepines reduce the tolerance to reward delay in rats. Psychopharmacology 86:147–152
Tomkins DM, Costall B, Kelly ME (1990a) Actions of ritanserin and DOI on the elevated X-maze. Psychopharmacology 101:S57
Tomkins TM, Costall B, Kelly ME (1990b) Release of suppressed behaviour of rat on the elevated X-maze by 5-HT3 antagonists injected into the basolateral amygdala. J Psychopharmacol 4:262
Traber J, Glaser T (1987) 5-HT1A receptor-related anxiolytics. TIPS 8:432–437
Tye NC, Iversen SD, Green AR (1979) The effects of benzodiazepine and serotonergic manipulations on punished responding. Neuropharmacology 18:689–695
Upton N, Blackburn TP (1991) Anxiolytic-like activity of the selective 5-HT3 receptor antagonnist, BRL 46470A, in the rat elevated X-maze. Br J Pharmacol 102:253P
VanderMaelen CP, Matheson GK, Wilderman RC, Patterson LA (1986) Inhibition of serotonergic dorsal raphe neurones by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 129:123–130
Van Wijngaarden IK, Thulp MThM, Soudin W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188:301–312
Viana MB, Tomaz CAB, Graeff FG (1992) Effect of diazepam in rats placed on the elevated T-maze, a possible experimental model of anxiety and memory. In: VII Annual Meeting of FESBE (Caxambu, Brazil, Abstr, p 49)
Whitton P, Curzon G (1990) Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology 100:138–140
Winslow JT, Insel TR (1991) Serotonergic modulation of the rat pup ultrasonic isolation call test; studies with 5-HT1 and 5-HT2 subtype selective agonists and antagonists. Psychopharamcology 105:513–520
Wright IK, Heaton M, Upton N, Marsden CA (1992) Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharamcology 107:405–414
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Handley, S.L., McBlane, J.W. 5HT drugs in animal models of anxiety. Psychopharmacology 112, 13–20 (1993). https://doi.org/10.1007/BF02247358
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02247358